DOT1L and nonpapillary renal cell carcinoma: Furthermore, the complete interaction network of Dot1l in ccRCC is still unclear and needs to be fully elucidated in future study, especially for the functional role of Dot1l in ccRCC. Finally, future studies can focus on the therapeutic effect of Dot1l on ccRCC patients, as Dot1l inhibitors have been tested for MLL treatments